However, in T2DM participants with or without obesity, the use of GLP-1 RAs was not associated with a significant reduction in MACE compared with SGLT-2 inhibitors (RR 0.94 [0.83–1.06] and 0.97 [0.81–1.15]). The gene discussed is GLP1R; the disease is Obesity.